VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
dmLT
Phase 2
Biologic
P
PATH
1
Indications
6
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Vaccine
2 trials
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
Completed
·
P
PATH
·
Phase 1
·
NCT03404674
·
50 enrolled
Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh
Completed
·
P
PATH
·
Phase 1/2
·
NCT02531802
·
475 enrolled
Immune Response
1 trial
A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya
Completed
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 1
·
NCT04826094
·
143 enrolled
Immunogenicity
1 trial
Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant
Completed
·
U
University of Vermont
·
Phase 1
·
NCT03922061
·
29 enrolled
Adjuvant
1 trial
Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults
Completed
·
P
PATH
·
Phase 1/2
·
NCT01739231
·
81 enrolled
Diarrhea
1 trial
Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults
Active, not recruiting
·
N
National Institute of Allergy and Infectious Diseases (NIAID)
·
Phase 2
·
NCT06692907
·
72 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
6 trial records for dmLT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
dmLT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for dmLT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
PATH company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Biologic
[2]
Highest Phase
Phase 2
[1]
Company
P
PATH
Related News